A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
← catalyst calendarNCT07015697 · readout in 865 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With AstraZeneca.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
76estimated
Sites
31
Countries
Brazil, France, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-17 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Recurrent or Metastatic Solid Tumors
Intervention
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, ENHERTU®
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)
measured From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
Area Under Curve (AUC)
measured From the start of trial intervention to last dose, up to approximately 9 months
Number of Participants with Dose limiting toxicities (DLT) During the Dose-Escalation Phase
measured From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed